REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc (IMGO). (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing ...
52% had reductions in mutant allele frequencies, including ASXL1 85% of evaluable patients demonstrated improved or stable fibrosis scores 90% of transfusion independent patients had stable or ...
100% (29/29) of patients experienced platelet count reduction to within normal ranges (150 – 400 x 109/L). 90% (26/29) of patients achieved a platelet count of less than 400 x 109/L without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results